Compare Enovix Corporation (ENVX) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enovix Corporation vs Natera Inc. Common Stock — how do they compare? Enovix Corporation trades at $2.39 (market cap $550.82M), while Natera Inc. Common Stock trades at $394.6 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 103.5× Enovix Corporation's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Enovix Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enovix Corporation for 11 Days and Natera Inc. Common Stock for 0 Days on average.
| ENVX | NTRA | |
|---|---|---|
Market Cap | $550.82M | $57.03B |
Volume | 5,977,872 | 1,131,157 |
Sector | Industrials | Health |
52-Week High | $13.19 | $425.64 |
52-Week Low | $2.44 | $179.42 |
Typical Hold Time | 11 Days | 0 Days |
Enterprise Value | $612.51M | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVX trades at $2.51, down 3.09% on the day, reflecting bearish technical signals and negative profitability. The company reported a net loss of -$156.74M in 2025, with revenue of $31.82M, while recent quarterly EPS has consistently beaten expectations. Key developments include a CEO transition in August 2026 and expansion of drone battery capacity in South Korea.
Despite deep losses and cash burn, analyst consensus remains bullish with a $9.60 price target, citing potential in defense and smartphone battery markets. Risks include high cash burn, leadership changes, and competitive pressures. The stock's outlook hinges on successful commercialization and margin improvement.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enovix Corporation
Enovix designs and manufactures advanced silicon-anode lithium-ion batteries. Its technology aims to provide high energy density and improved performance for mobile devices and consumer electronics.
Read more on ENVX →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
